Short Communication: Differences in 5-Year Survival after Cancer Diagnosis between HIV Clinic Enrollees and the General U.S. Population

Research output: Contribution to journalArticle

Abstract

A total of 236 people with HIV (PWH) with cancer diagnosed between 1997 and 2014 in the Johns Hopkins HIV Clinical Cohort (JHHCC) were compared with a sample from NCI's Surveillance, Epidemiology, and End Results (SEER) Program, presumed to be HIV negative. Using G-computation with random survival forest methods, we estimated 5-year restricted mean survival time (RMST) differences by HIV status. Sensitivity analyses were performed among non-AIDS defining cancers, males, females, and stratifying PWH by CD4 ≤ 200 or >200 cells/mm3 at cancer diagnosis. PWH with CD4 ≤ 200 cells/mm3 had decreased survival compared with those in SEER (-7 months; 95% CI =-13 to-2). Women with HIV and CD4 ≤ 200 cells/mm3 at cancer diagnosis had lower survival than SEER women (-10 months; 95% CI =-18 to-2). In the total population, there was no significant difference in 5-year RMST; however, women with HIV and low CD4 had higher mortality despite accounting for stage at diagnosis and first course of cancer treatment.

Original languageEnglish (US)
Pages (from-to)116-118
Number of pages3
JournalAIDS research and human retroviruses
Volume36
Issue number2
DOIs
StatePublished - Feb 2020

Keywords

  • CD4
  • HIV infection
  • cancer
  • cancer survival

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Short Communication: Differences in 5-Year Survival after Cancer Diagnosis between HIV Clinic Enrollees and the General U.S. Population'. Together they form a unique fingerprint.

  • Cite this